Granted Patent B2

US 12,473,294 · App. 18/511,018 · Granted Nov 18, 2025

Inventors: Erika Marina Vieira Araujo (Woodbridge, CT); Michael Berlin (Flemington, NJ); Steven M. Sparks (Guilford, CT); Jing Wang (Milford, CT); Wei Zhang (Madison, CT)

Assignee: Arvinas Operations, Inc.

C07D487/04A61K45/06C07D519/00

Abstract

Claims (65)

1 . A method of treating a disease or a disorder associated with LRRK2, comprising administering an effective amount of a compound having the chemical structure:

PTM-L-CLM,

or a pharmaceutically acceptable salt thereof,

wherein:

(a) the CLM is:

wherein:

W is selected from CH 2 , O, CHR, C═O, SO 2 , NH, N, optionally substituted cyclopropyl group, optionally substituted cyclobutyl group, and N-alkyl;

W 3 is C or N;

each X is independently selected from absent, O, S, and CH 2 ;

Y is selected from CH 2 , —C═CR′, NH, N-alkyl, N-aryl, N-heteroaryl, N-cycloalkyl, N-heterocyclyl, O, and S;

Z is selected from absent, O, S, and CH 2 ;

G and G′ are independently selected from H, unsubstituted or substituted linear or branched alkyl, OH, R′OCOOR, R′OCONRR″, CH 2 -heterocyclyl optionally substituted with R′, and benzyl optionally substituted with R′;

Q 1 , Q 2 , Q 3 , and Q 4 represent C or N independently substituted with H, R, N, or N-oxide;

A is independently selected from H, unsubstituted or substituted linear or branched alkyl, cycloalkyl, —Cl, and —F;

m′ is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

R is a bond, H, —CONR′R″, —C(═O)R′, —OR′, —NR′R″, —SR′, —SO 2 R′, —SO 2 NR′R″, —CR′R″—, —CR′NR′R″—, (—CR′O) n′ R″, optionally substituted heterocyclyl, aryl, optionally substituted alkyl-aryl, heteroaryl, unsubstituted or substituted linear or branched alkyl, optionally substituted alkoxyl group, optionally substituted heterocyclyl, —P(O)(OR′)R″, —P(O)R′R″, —OP(O)(OR′)R″, —OP(O)R′R″, —Cl, —F, —Br, —I, —CF 3 , —CN, —NR′SO 2 NR′R″, —NR′CONR′R″, —CONR′COR″, —NR′C(═N—CN)NR′R″, —C(═N—CN)NR′R″, —NR′C(═N—CN)R″, —NR′C(═C—NO 2 )NR′R″, —SO 2 NR′COR″, —NO 2 , —CO 2 R′, —C(C═N—OR′)R″, —CR′═CR′R″, —CCR′, —S(C═O)(C═N—R′)R″, —SF 5 and —OCF 3 , wherein at least one R or W is modified to be covalently joined to the PTM, L, or the CLM;

R′ and R″ are independently selected from a bond, H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclic, and optionally substituted heterocyclyl;

n′ is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

represents a single bond or a double bond; and

represents a bond that may be stereospecific or non-stereospecific;

(b) the PTM is selected from:

and

wherein

of the PTM indicates the site of attachment with a chemical linking group; and

(c) the L is a bond or is a chemical linking group that covalently couples the CLM to the PTM and is selected from:

wherein:

N* is a nitrogen atom that is covalently linked to the CLM or the PTM, or that is shared with the CLM or the PTM;

each m, n, o, and p is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;

and the chemical linker group is optionally substituted with 1, 2, 3, or 4 substitutions independently selected from halogen and C1-4 alkyl and wherein the disease or the disorder associated with LRRK2 is a neurodegenerative disease selected from the group consisting of Parkinson's disease, Parkinson disease with dementia, Parkinson's disease at risk syndrome, dementia with Lewy bodies, Lewy body variant of Alzheimer's disease, combined Parkinson's disease and Alzheimer's disease, multiple system atrophy, striatonigral degeneration, olivopontocerebellar atrophy, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, and Shy-Drager syndrome.

2 . The method of claim 1 , where LRRK2 is characterized by a G2019S mutation.

3 . The method of claim 1 , wherein the neurodegenerative disease is Parkinson's disease.

4 . The method of claim 1 , wherein the PTM is:

wherein

indicates a site of attachment of the L or the CLM, and wherein each PTM is coupled to at least one L or to the CLM.

5 . The method of claim 1 , wherein the CLM is:

6 . The method of claim 4 , wherein the CLM is:

7 . The method of claim 1 , wherein the PTM is:

or wherein indicates a site of attachment of the L or the CLM, and wherein the PTM is coupled to the L or to the CLM.

8 . The method of claim 1 , wherein:

(a) the CLM is:

wherein:

of the CLM indicates the point of attachment with the L or the PTM; and

N* is a nitrogen atom that is shared with the L or the PTM;

(b) the PTM is:

wherein

of the PTM indicates point of attachment with the L or the CLM;

(c) the L is selected from:

wherein

or * indicates the site that is covalently linked to the CLM or the PTM, or that is shared with the CLM or the PTM; or

(d) a combination thereof.

9 . The method of claim 1 , wherein:

(a) the CLM is:

wherein:

of the CLM indicates the point of attachment with the L or the PTM; and

N* is a nitrogen atom that is shared with the L or the PTM;

(b) the PTM is:

wherein

of the PIM indicates the point of attachment with the L or the CLM; and

(c) the L is selected from:

wherein

or * indicates the site that is covalently linked to the CLM or the PTM, or that is shared with the CLM or the PTM.

10 . The method of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

11 . The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Assignments (1)

Continuity (3)

References Cited (18)